Caris Life Sciences Inc (CAI) vs peers

$35.82

Latest weekly close · Market cap $10.1B

CAI's P/S is 10.2x, compared with 7.9x at the middle of 7 peers.

Peer group: Biotechnology. Updated .

CAI and Biotechnology, ranked by P/S
StockP/SOwn 5-year percentile
CAICaris Life Sciences Inc10.2×98
MRNAModerna38.3×99
NTRANatera Inc22.5×100
VRTXVertex Pharmaceuticals10.7×72
ABBVAbbVie7.9×100
GILDGilead Sciences6.5×99
AMGNAmgen6.5×99
REGNRegeneron Pharmaceuticals5.6×41
RVMDRevolution Medicines Incn/mn/m, not ranked
Peer median7.9×
How to read this comparison

Up to eight covered companies in the same industry, largest market value first.

P/S divides market value by revenue over the last twelve months. The peer median leaves out CAI and stocks without a reading.

Each percentile compares a stock with its own weekly readings over the last five years, so 20 means its P/S is above 20% of its own past readings. It needs at least 26 weeks of history. It is not a rank against the other stocks in this table.

Different growth rates, margins and financial risks can explain different multiples. Stocks without positive revenue have no reading.

CAI versus the peer median

+30%

CAI
10.2×
Peer median
7.9×
Own 5-year median
6.0×

Source: SEC company filings and weekly market prices. Multiples use the last twelve months of financial results. Updated .

How the valuation data is built